Seattle Genetics (SGEN) - FREE Research Report

Dobmeier Eric who is Chief Operating Officer at Seattle Genetics sold 56,010 shares at $47.92 on Jan. 23, 2014. Following this transaction, the Chief Operating Officer owned 77,833 shares meaning that the stake was reduced by 41.85% with the 56,010-share transaction.

The shares most recently traded at $46.68, down $1.24, or 2.65% since the insider transaction. Historical insider transactions for Seattle Genetics go as follows:

  • 4-Week # shares sold: 1,201
  • 12-Week # shares sold: 1,201
  • 24-Week # shares sold: 103,201

The average volume for Seattle Genetics has been 846,700 shares per day over the past 30 days. Seattle Genetics has a market cap of $5.9 billion and is part of the health care sector and drugs industry. Shares are up 19.3% year-to-date as of the close of trading on Thursday.

Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS, has accelerated approval form the U.S. Currently there are 3 analysts that rate Seattle Genetics a buy, 2 analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SGEN - FREE

TheStreet Quant Ratings rates Seattle Genetics as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and feeble growth in its earnings per share. Get the full Seattle Genetics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

How Sprint, Sirius XM and Interactive Brokers Could Blast Higher in April

Here's Why Sprint, Interactive Brokers and SiriuxXM Could Blast Higher in April

Interactive Brokers Stock Downgraded by Wells Fargo

Sag Harbor's Sanford Finds Value in Brokerages, ETF Managers

4 Unsung But Fabulous Financial Stocks